BRAF^V600E Mutation Gene And Survivin Protein In The Expression Of Papillary Thyroid Cancer

Objective:To investigate the BRAFV600E mutant gene and the Survivin protein in papillary thyroid carcinoma tumor expression, through the pathology research and the grouping contrast, carries on the analysis to the papillary thyroid carcinoma tumor’s BRAFV600E mutant gene and the Survivin protein, by the time can through to both in human body’s abnormal expression understand that the thyroid gland carcinogenesis, the development possibility, provides the reliable basis for the clinical diagnosis and the treatment.Method:This research carries on the papillary thyroid carcinoma cancer cell and the normal thyroid gland cell and the benign tyroma cell the contrast (DHPLC), the technology examines the BRAFV600E mutant gene through the denaturation highly effective liquid chromatography, in the utilization immunity histochemistry staining technique observation papillary thyroid carcinoma tumor Survivin the protein expression. Divides into two groups76example examination’s specimen, a group for papillary thyroid carcinoma tumor specimen53examples, control group for normal thyroid gland organization specimen and benign tyroma specimen, the normal thyroid gland organizes10examples, benign tyroma13examples. Conducts the check analysis research to two groups of specimens, is mainly revolving the protein and the gene histopathology structure and the papillary thyroid carcinoma cancer lymph node shift relations and so on relevant data launches. Results:1, BRAFV600E PTC group BRAFV600E the mutation rate was54.72%mutation (29/53) in the control group were not detected in the mutant, there were significant differences between the two groups (X2=8.06, P<0.01and X2=12.69, P<0.01). Sensitive of67.4%, specificity of100.0%. PTC mutations in male patients with a ratio of12/19, and17/34for women. Gender differences in the mutation was not statistically significant (t=0.85,P>0.05). The age at onset, less than45-year-old mutation rate of14/30, and more than45-year-old mutation ratio of15/23, the same difference was not statistically significant (t=2.38,P>0.05).21cases occurred in patients with cervical lymph node metastases were detected in15out of the mutation, while the other32patients without lymph node metastasis in patients with mutations in only14cases occur between the two groups was statistically significant (t3.92, P<0.05), suggesting that BRAFV600E mutations are associated with cervical lymph node metastasis, whereas gender, age, capsule invasion no relevance.2, survivin immune histochemical results survivin positive signal was mainly localized in the cytoplasm, the thickness ranging from brown or brown granules. Survivin expression in papillary thyroid carcinoma in approximately53%(26/53), no expression in normal thyroid tissue,2patients (20.0%) were weakly positive thyroid adenoma, there are significant differences between groups (X2=6.45, P<0.05and X2=6.16, P<0.05), sensitivity was64.4%, specificity of89.34%in the PTC group, male patients with mutations of the ratio is10/19, the ratio of female patients with mutations in is16/34, sex the difference was not statistically significant (t=0.15, P>0.05); less than45years of age the rate of mutations in patients is12/30, greater than45-year-old patients with mutations of the ratio is14/23, the difference was not statistically significance (t=3.52, P>0.05); lymph node metastasis in patients with mutations of the ratio of16/21, no transfer of patients10/32chance of mutation, the difference was statistically significant (t=10.25, P<0.05.)Conclusion:The BRAFV600E mutant gene and the Survivin expression and the lymph node shift have the remarkable relations, in has the lymph node to shift in the case, the BRAFV600E sudden change masculine gender rate and the Survivin masculine gender rate are higher than the corresponding non-lymph node shift case, the difference have statistics significance.